Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
Mark Lebwohl, Andrew Blauvelt, Alan Menter, et al.
American Journal of Clinical Dermatology (2019) Vol. 20, Iss. 6, pp. 863-871
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 11, pp. 2461-2498
Open Access | Times Cited: 261
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 84
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis
Paolo Gisondi, Maria Concetta Fargnoli, Paolo Amerio, et al.
Italian Journal of Dermatology and Venereology (2022) Vol. 157
Open Access | Times Cited: 62
Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*
Kristian Reich, Kenneth B. Gordon, Bruce Strober, et al.
British Journal of Dermatology (2021) Vol. 185, Iss. 6, pp. 1146-1159
Open Access | Times Cited: 56
Anti IL-17 in psoriasis
Karen Ly, Mary Patricia Smith, Quinn Thibodeaux, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 11, pp. 1185-1194
Closed Access | Times Cited: 75
Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
Kim Papp, Mark Lebwohl, L. Puig, et al.
British Journal of Dermatology (2021) Vol. 185, Iss. 6, pp. 1135-1145
Open Access | Times Cited: 39
Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience
Maria Concetta Fargnoli, Maria Esposito, Paolo Dapavo, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 3, pp. 693-700
Closed Access | Times Cited: 33
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
Carmen Rodríguez‐Cerdeira, José Luís González-Cespón, Erick Martínez‐Herrera, et al.
Italian Journal of Dermatology and Venereology (2021) Vol. 156, Iss. 5
Closed Access | Times Cited: 32
Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
Kristian Reich, Diamant Thaçi, Georg Stingl, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00683-adv00683
Open Access | Times Cited: 20
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
S. Wu, Yuanyuan Xu, Lihua Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 4
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study
Amera Elzubeir, Juliet High, Matthew Hammond, et al.
BMJ Open Gastroenterology (2025) Vol. 12, Iss. 1, pp. e001596-e001596
Open Access
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
Marco Galluzzo, Giacomo Caldarola, Clara De Simone, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1299-1310
Open Access | Times Cited: 24
Gastroenterological safety of IL-17 inhibitors: a systematic literature review
Bénédicte Caron, Jean‐Yves Jouzeau, Pierre Miossec, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 2, pp. 223-239
Closed Access | Times Cited: 23
Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3
Kristian Reich, Lars Iversen, L. Puig, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 8, pp. 1275-1283
Open Access | Times Cited: 14
The safety of brodalumab for the treatment of psoriasis
Helena Iznardo, L. Puig
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 4, pp. 365-372
Closed Access | Times Cited: 22
Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis
Marta Krzysztofik, Paweł Brzewski, Przemysław J. Cuber, et al.
Pharmaceuticals (2023) Vol. 17, Iss. 1, pp. 14-14
Open Access | Times Cited: 7
Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study
Shinichi Imafuku, Chika Ohata, Yukari Okubo, et al.
Journal of Dermatological Science (2022) Vol. 105, Iss. 3, pp. 176-184
Closed Access | Times Cited: 12
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Kristian Reich, Luca Bianchi, A. Khemis, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 2, pp. 453-468
Open Access | Times Cited: 2
Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
Seong Jun Seo, Bong Seok Shin, Joo‐Heung Lee, et al.
The Journal of Dermatology (2020) Vol. 48, Iss. 6, pp. 807-817
Open Access | Times Cited: 16
Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
Yukie Yamaguchi, Nobumichi Takatsu, Kenji Ootaki, et al.
The Journal of Dermatology (2020) Vol. 47, Iss. 6, pp. 569-577
Open Access | Times Cited: 13
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Jo Lambert, Jes B. Hansen, Anne Sohrt, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 4, pp. 1265-1275
Open Access | Times Cited: 11
Management of moderate to severe psoriasis with brodalumab—Real‐world evidence from the LIBERO study
Ralph von Kiedrowski, Torsten Hinz, Georg Mauer, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access | Times Cited: 1
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score
Husein Husein‐ElAhmed, Sara Husein-ElAhmed
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 10, pp. 1148-1155
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top